healthy subjects
Conditions
Interventions
None listed
Sponsors
Antibiotice S.A.
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Outcome results
None listed
A randomized, balanced, two-treatment, two-sequence, single oral dose, two stage crossover adaptative bioequivalence study of Rifaximin 200 mg film-coated tablets (Antibiotice SA) vs. Normix® 200 mg, film- coated tablets (Alfasigma S.P.A) in healthy subjects under fed conditions
For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms
Source: EU CTIS · Data processed: May 23, 2026